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Abstract Partial cDNAs coding for each of the three human 
inter-a-trypsin inhibitor (ITI) heavy chains were expressed in a 
bacterial plasmid system and rabbits were immunised with the 
fusion peptides obtained. Despite the strong sequence homology 
of these chains, the antisera turned out to be highly specific in the 
analysis of corresponding mRNA translation products or par- 
tially digested serum ITI. Besides classical serum ITI members, 
their use in Western blotting made it possible to evidence an 
H3-related ITI form and a low-amount HI-related HC/bikunin 
component. The relative levels of ITI family members was further 
studied in baboon and foetal calf sera. 
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I. Introduction 
Inter-a-trypsin i hibitor (ITI) is a human plasma proteinase 
inhibitor with an apparent molecular mass of 220 kDa. Besides 
its proteinase inhibitory function, little is presently known con- 
cerning its actual physiological role, even though it has been 
recently reported that ITI-related proteins may act as extracel- 
lular matrix stabilizing factors [1-3]. Its multichain structure 
was demonstrated through the identification of two different 
mRNA populations, one of them coding for heavy chains (H) 
and the other for a light chain (L) [4]. The peptide sequence of 
the light chain, deduced from that of the cDNA [5,6], corre- 
sponds to the precursor of two tandemly arranged proteins, 
~l-microglobulin a d bikunin (responsible for the protease in- 
hibitory activity), which separate at the time of ITI maturation 
[7,8]. Three mRNAs coding for distinct heavy-chain peptides, 
called H1, H2 and H3, were then described [9-11]; they showed 
highly similar amino acid sequences. Further, the ITI-related 
proteins are synthesized in the liver by four genes located on 
three different chromosomes [12]. 
The purification and N-terminal micro-sequencing of serum 
ITI-related proteins led to the description of two components 
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[13]: (1) ITI (225 kDa) composed of HC1, HC2 (maturation of
H1 and H2 precursors) and bikunin; (2) pre-~-trypsin inhibitor 
(P~I, 125 kDa) composed of HC3 (maturation of H3) and 
bikunin. A further one, described as being composed of 
HC2 + bikunin [13] with a mass close to that of Pod, was re- 
cently called inter-c~-like inhibitor (Ic~LI) [14]. As for ITI, these 
proteins cannot be dissociated into their constituent chains 
under reducing conditions. The assembly between heavy and 
light chains has been shown to be mediated through chon- 
droitin sulphate linkage in the ITI molecule [15], an unusual 
structure in plasma proteins. Indeed, a glycosaminoglycan 
(GAG) chain carried by bikunin covalently cross-links the two 
chains in PctI and HC2/bikunin [16,17] and the three chains in 
ITI [18]. 
In the present study, we used cDNA fragments correspond- 
ing to part of ITI H1, H2 and H3 chains in order to produce 
immunogenic peptides in a bacterial plasmid expression system. 
The highly specific polyclonal antibodies obtained allowed a 
specific analysis of ITI-family members in serum and led to the 
postulate that each heavy chain contributes to the ITI and 
HC/bikunin composition. 
2. Materials and methods 
2.1. Chemicals and mater&& 
The pMALc vector, £ coli TB1 strain, amylose resin and anti-MBP 
antiserum were obtained with the 'Protein fusion and purification sys- 
tem' kit purchased from New England Biolabs. The cDNA inserts were 
prepared using the Geneclean II kit from BIO 101; restriction enzymes 
and ligase from GIBCO BRL were used according to the manufac- 
turer's instructions. Isopropyl fl-D-thiogalactoside (IPTG), Freund's 
complete and incomplete adjuvants were from Boehringer and Difco 
Laboratories. For the antiserum specificity characterization, radiola- 
beled translation products of human liver mRNAs were obtained using 
the Translation kit and [35S]methionine from GIBCO BRL and Amer- 
sham, respectively. Protein-A Sepharose from Pharmacia was used for 
immunoprecipitations. Therainbow-coloured protein high-molecular 
weight markers (14.3 200 kDa) from Amersham were routinely in- 
cluded in the run. For the ITI-related serum protein analysis, chon- 
droitin AC lyase from Arthrobacter aurescens (EC 4.2.2.5) was from 
ICN Biomedicals. Western blot was achieved using nitrocellulose heets 
from Shleicher and SchiJll with a 0.45-/tm pore size. Rabbit anti- 
[(H + L) ITI], anti-L ITI antisera were prepared as previously described 
[19]. The goat antirabbit IgG antiserum was from Dako, the horse- 
radish peroxidase antiperoxidase (PAP) complex prepared in rabbit 
was from ICN and 3,3'-diaminobenzidine tetrahydrochloride (DAB) 
was purchased from Sigma. The molecular mass tandards used (3(~ 
212 kDa) were from Pharmacia. All chemicals used were of analytical 
grade. 
2.2. Production of immunogenic ITI-H peptides 
The isolation of cDNA fragments was performed from the 2gtl 1 
clones named 2HuHITI-44 (analogous to2HuHITI-19), AHuHITI-9, 
AHuHITI-13, originally immunoscreened for the expression of either 
0014-5793/95/$9.50 © 1995 Federation of European Biochemical Societies. All rights reserved. 
SSDI  0014-5793(95)01103-X 
196 A. Hdron et al./FEBS Letters 374 (1995) 195-198 
ITI H chain [12,20], HI, H2 and H3, respectively. Each fragment was 
subcloned into the EcoRI site of the pMALc expression vector 
polylinker, in fusion with the malE gene-coding for the maltose-binding 
protein (MBP). The recombinant vectors were used to transfect the TB 1 
strain of E. coli [21]. The transfected cells were grown up to 4 x l0 s 
cells/ml. The expression of the fusion peptides was induced with IPTG, 
which was added to the culture to a final concentration f0.3 mM. Cell 
lysates were prepared in lysis buffer (10 mM di-sodium hydrogeno- 
phosphate, 30 mM NaCI, 0.25% (v/v) Tween°20, 10 mM fl-mercap- 
toethanol, 10 mM ethylenediamine-tetraacetic acid, 10 mM ethyl- 
eneglycoltetraacetic acid (EGTA), 100 mM phenylmethyl sulphonyl 
fluoride, pH 7.0) containing 1mg/ml ysozyme. After one freeze-thaw 
cycle, NaCI was added to a final concentration of 500 mM and the 
cellular debris were pelleted by centrifugation at20,000 rpm for 30 rain 
at 4°C (SW 27 Beckman rotor). The supernatant was diluted 1/5 with 
column buffer (10 mM sodium phosphate, 30 mM NaCI, I mM sodium 
azide, 10 mM fl-mercaptoethanol, 1 mM EGTA, 0.25% (v/v) Tween-20, 
pH 7.0) and was applied to an amylose resin column. The hybrid 
proteins linked to the resin were eluted with 10 mM maltose in column 
buffer. The proteins were concentrated by ultrafiltration on PM 30 
membranes (Amicon) and their level was estimated on microtiter plates 
by the Bradford method [22]. 
Anti-hybrid protein antibodies were raised in rabbits. Primary immu- 
nizations were carried out by intramuscular injections of 1 mg of hybrid 
protein in Freund's complete adjuvant. Booster injections consisting of 
1 mg of hybrid protein in Freund's incomplete adjuvant were given by 
the same route after 1 month and then every 2 weeks. Blood was taken 
1 week after each injection and antisera were stored at -20°C. 
2.3. Characterization of anti-MBP-H antisera 
The specificity of the anti-MBP-H antisera was investigated by: 
(1) immunoprecipitation f the translation products of human liver 
mRNAs obtained in mRNA-dependent rabbit reticulocyte lysates in 
the presence of [35S]methionine as previously described [4]; (2) analysis 
by Western blotting of serum proteins submitted to chondroitin AC 
lyase digestion according to [23], except that 4 mU of enzyme was used. 
2+4+ SDS-PAGE and Western blotting 
Immunoprecipitated products were analysed by sodium dodecyl 
sulphate-polyacrylamide gel lectrophoresis (SDS-PAGE) in discontin- 
uous polyacrylamide gels (stacking el 5%, separating el 14%) [24]. 
After electrophoresis and fixing, the gel was soaked in 20% (w/v) 2,5- 
diphenyloxazole scintillation grade in dimethyl sulphoxide, dried and 
fluorographed with Kodak XAR films at room temperature for 1 5 
days [25]. 
The ITI-related serum proteins and purified ITI [26] were analysed 
by SDS-PAGE in ExcelGels (Pharmacia), except hat home-made 5.5 
15% gradient gels were used, or in discontinuous polyacrylamide g ls 
(stacking el 5%, separating gel 7.5%). After electrophoretic ransfer of 
polyacrylamide g ls to nitrocellulose [27], proteins were revealed by the 
unlabeled antibody enzyme method [28]: each step was performed for 
30 min at room temperature in PBSTM (8 mM Na2HPO4, 2 mM 
KH2PO4, 500 mM NaCI, 0.1 g/1 merthiolate, 0.05% (v/v) Tween-20, pH 
7.0); nitrocellulose heets were successively incubated in specific antise- 
rum diluted 300-fold (anti-[(H + L) ITI], anti-L ITI) or 100-fold (anti- 
MBP-H), goat antirabbit IgG antiserum diluted 300-fold and PAP 
complex diluted 200-fold. Each step was followed by three 10-rain 
washes. Membranes were finally stained using 0.6 g/1 DAB and 0.01% 
(v/v) hydrogen peroxide in PBSTM. 
3. Results 
3.1. Obtaining o f  H-specific antisera f rom bacterial expression 
o f  IT I -H  cDNAs 
The cDNA fragments excised from Agtl l  clones (EcoRI- 
SmaI for HI ,  EcoRI -EcoRI  for H2 and EcoRI-AccI  for H3) 
corresponded to the central and/or the 3' end of ITI heavy- 
chain mRNAs.  Their respective sizes were 1163, 1190 and 1634 
bp and they coded for three peptides with a theoretical mass 
of 42,146, 43,731 and 61,136 Da. With respect o the mature 
heavy chains (HC), they contained the 138, 320 and 304 C- 
1 2 3 4 5 1 2 3 4 
kDa 
200- -  
92.5 - -  
41t - -  
kDa 
A B 
Fig. 1. Analysis of anti-MBP-H antisera. (A) Immunoprecipitations f 
translation products from human liver mRNAs characterized by SDS- 
PAGE (14% acrylamide) and autoradiography. Immunoprecipitation 
was performed with anti-MBP-H1 (lane 1), anti-MBP-H2 (lane 2), 
anti-MBP-H3 (lane 3), anti-[(H + L) ITI] antiserum (lane 4) and non- 
immune rabbit serum (lane 5). (B) Human serum submitted to limited 
digestion with chondroitin AC lyase was analysed by SDS-PAGE (Ex- 
celGel 5.5 15% gradient), electrotransferred to nitrocellulose and 
probed with anti-MBP-H3 (lane 1), anti-MBP-H2 (lane 2), anti-MBP- 
H1 (lane 3) and anti-[H + L] ITI (lane 4) antisera. The scales corre- 
spond to molecular weight standards. Cathode at the top. 
terminal amino acids, respectively. At their 5' end, all these 
inserts included an EcoRI restriction site present either in the 
cDNA (HI) or in the form of an artificial cloning site (H2 and 
H3). Such a site being in the same reading frame in pMALc and 
2gt l l  vectors, proteins fused with the malE gene product 
(MBP) could be directly obtained. These fusion proteins could 
be further purified as a result of the affinity of the carrier 
protein (MBP) for an amylose resin. When studied in SDS- 
PAGE, they turned out to be heterogeneous with masses rang- 
ing from 42 kDa (MBP alone) to 105 kDa (MBP-H3). Western 
blotting and probing with an anti-[(H + L) ITI] antiserum only 
evidenced the heaviest fusion proteins, 84 kDa for MBP-H1, 
85 kDa for MBP-H2 and 105 kDa for MBP-H3 (results not 
shown). 
After immunization of rabbits with the concentrated fusion 
protein preparations (1 2 mg/ml), the polyclonal antisera ob- 
tained were analysed by immunoprecipitation f the translation 
products from human liver mRNAs  (Fig. 1A). As previously 
described [12], the anti-[(H + L) ITI] antiserum revealed three 
heavy chains H1 (92 kDa), H2 (98 kDa), H3 (107 kDa) and one 
light chain (45 kDa) (Fig. 1A, lane 4). Immunoprecipitation f 
the same products with anti-MBP-H1, anti-MBP-H2 and anti- 
MBP-H3 specifically detected H1, H2 and H3, respectively. 
Similar results were obtained with translation products from 
baboon liver mRNAs.  No reaction was observed with a non- 
immunised rabbit serum (Fig. 1A, lane 5) or an anti-MBP 
antiserum (result not shown). 
Serum submitted to limited digestion by chondroitin AC 
lyase, a procedure known to give rise to free ITI heavy chains 
[23], was analysed by SDS-PAGE and Western blotting with 
anti-ITl antisera. As shown in Fig. 1B, anti-[(H + L) ITI] anti- 
serum detected four bands corresponding to native undigested 
ITI (220 kDa), an intermediary product (170 kDa) and two 
bands between 70 and 85 kDa. Each anti-MBP-H antiserum 
evidenced a particular free H form with respective masses of 72 
kDa (anti-MBP-H1), 84 kDa (anti-MBP-H2) and 75 kDa (anti- 
MBP-H3). 
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Fig. 2. Western blot analysis of serum ITI-related proteins. Purified 
human ITI (lane 1), human (lane 2), baboon (lane 3) or foetal calf serum 
(lane 4) were analysed by SDS-PAGE (7.5% acrylamide), electrotrans- 
ferred to nitrocellulose and probed with anti-L ITI (A), anti-MBP-H1 
(B), anti-MBP-H2 (C) and anti-MBP-H3 (D) antisera. The scale corre- 
sponds to molecular weight standards. Cathode at the top. 
3.2. Immunochemical nalysis of  serum ITI-related proteins 
Human, baboon and foetal calf serum as well as a purified 
human ITI fraction were analysed by SDS-PAGE followed by 
electrotransfer on nitrocellulose and immunochemical detec- 
tion with anti-L IT! and anti-MBP-H antisera (Fig. 2). In 
human serum, three components (115, 125 and 220 kDa) were 
revealed with anti-L ITI (Fig. 2A, lane 2). The l15-125-kDa 
proteins reacted with anti-MBP-H2 and anti-MBP-H3 (Fig. 
2C,D, lane 2) and occasionally as a faint signal with anti-MBP- 
HI. The 220-kDa protein gave similar signals with anti-MBP- 
H1 (Fig. 2B, lane 2) and anti-MBP-H2 (Fig. 2C, lane 2); the 
reaction with anti-MBP-H3 was weak though present in a con- 
centrated fraction (Fig. 2D, lane 1). Several individual human 
serum samples were tested and gave identical results (data not 
shown). 
In baboon serum, the results obtained with the same antisera 
were similar: among the two major forms (120 and 200 kDa) 
evidenced with anti-L ITI (Fig. 2A, lane 3), the former reacted 
with anti-MBP-H2 (Fig. 2C, lane 3), and particularly with anti- 
MBP-H3 (Fig. 2D, lane 3), while the latter was marked by 
anti-MBP-H1 and anti-MBP-H2 antisera (Fig. 2B,C, lane 3). 
In foetal calf serum, two major forms (130 and 240 kDa) were 
evidenced with anti-L ITI (Fig. 2A, lane 4). The 130-kDa form 
only reacted with anti-MBP-H2 (Fig. 2C, lane 4). The 240-kDa 
protein was clearly marked by anti-MBP-H2 (Fig. 2C, lane 4) 
and more weakly by anti-MBP-H3 (Fig. 2D, lane 4) but failed 
to react with anti-MBP-H 1. Elsewhere, an anti-MBP antiserum 
did not give any immunochemical reaction with human, ba- 
boon and foetal calf sera or the ITI preparation (results not 
shown). 
4. Discussion 
The proteins of the ITI family are basically composed of four 
polypeptide chains, HI, H2, H3 and L. After maturation proc- 
essing, these components are thought o be assembled through 
carbohydrate cross-links to yield different covalent structures 
among which only three, ITI (HCl/HC2/bikunin), Ps i  (HC3/ 
bikunin) and HC2/bikunin, have been characterized [13,16,17]. 
Since the distribution of heavy chains within the ITI family is 
not rigorously defined, we chose to produce immunogenic pep- 
tides from partial cDNAs of H1, H2 and H3 with a bacterial 
expression system in order to obtain antisera specifically di- 
rected against hese chains. The observed masses of the hybrid 
proteins MBP-H obtained and their reactivity with an anti- 
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[(H + L) ITI] antiserum showed that the reading frame of the 
inserts was preserved in the recombinant plasmids and led to 
the synthesis in E. coli of an ITl-related peptide domain. The 
immunization of rabbits with the hybrid proteins MBP-H1, 
MBP-H2 and MBP-H3 resulted in highly specific H chain 
polyclonal antisera. As MBP is a strictly bacterial protein, the 
anti-MBP activity of these new antisera was unlikely to restrict 
in any way their use for the analysis of human products and 
this turned out to be true. Despite the high sequence similarity 
of ITI heavy chains [11], the anti-MBP-H antisera did not show 
any cross-reaction between them (Fig. 1). Within the frame- 
work of the present study, they may, therefore, be considered 
as anti-H1-, anti-H2- and anti-H3-specific antisera. 
The study of ITI-related human serum proteins howed two 
main groups displaying an immunochemical reactivity with 
both anti-L (bikunin) and anti-H (heavy chain) antisera. The 
first one (220 kDa), corresponding to ITI, showed expected 
reactivities towards the anti-L, H1 and H2 antisera; a further 
H3 reactivity could be clearly demonstrated in the purified ITI 
preparation and was occasionally observed in serum as a very 
weak signal. The second group (115-125 kDa) corresponded to
two-chain structures: (1) the PctI (125 kDa), composed of HC3 
and bikunin [16]; (2) the HC2/bikunin complex (130 kDa) [17], 
also called IctLI [14]; and (3) a 115-kDa protein occasionally 
seen with both anti-L and anti-H1 antisera, therefore, corre- 
sponding to an HCl/bikunin form, whose existence has been 
previously postulated [17]. 
Baboon serum gave results virtually identical with those of 
human serum, except hat the P~I/I~LI forms (120 kDa) were 
primarily marked by the anti-H3 antiserum and the observed 
size of baboon ITI was smaller, in keeping with earlier findings 
[5,12]. Contrasting results were obtained in foetal calf serum: 
besides a slightly higher molecular mass, ITI only displayed L, 
H2 and H3 reactivities and the 120-kDa protein group was 
restricted to HC2/bikunin. Despite the low reactivity of our 
antisera towards bovine proteins, these results are in total 
agreement with data obtained by protein-sequencing [29] where 
ITI (236 kDa) was composed of H2 and H3 heavy chains linked 
to bikunin and a 126-kDa form involved one H2 heavy 
chain + bikunin; the latter complex would correspond to ESF, 
the extracellular matrix stabilizing factor previously reported 
[11. 
In the originally described composition of ITI [13] as well as 
in a further study [23], chemical treatment and/or enzymatic 
digestion of ITI were used before the identification of its com- 
ponents by N-terminal-sequencing; thenumber and nature of 
chains involved in the native molecule could, therefore, not be 
accurately determined. Indeed, several elements challenge the 
commonly accepted composition of ITI, viz. only two heavy 
chains (HC1 and HC2) + bikunin: (1) in foetal calf serum, ITI 
is devoid of the HC1 chain and composed of HC2, HC3 and 
bikunin chains as herein described in agreement with the pro- 
tein-sequencing results [29]; (2) the H3 chain is found in human 
serum ITI, although in very low amounts, thus explaining why 
it had not been previously detected by protein-sequencing; 
(3) acute-phase mediators induce variations in the transcription 
rates of ITI genes, including opposite ffects on ITI H 1 and H2 
genes [30]; (4) Wisniewski et al. [31] recently purified a serum 
protein with high affinity for TSG-6, a member of the hyalad- 
herin family; this protein was shown to be an ITI molecule 
which only displayed H2 and bikunin chains by protein-se- 
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quencing; furthermore, the same component was found in su- 
pernatants of HepG2 cells, which in fact synthesise an IT / form 
only composed of HC2 and bikunin chains [32]. We, therefore, 
propose a multichain structure for serum ITI involving two 
identical or two different heavy chains, with a major involve- 
ment of i l l  and H2. Given the molecular mass of IT! compared 
with that of its components (heavy chains, bikunin and the 
GAG link) and the nature of the ITI-like protein produced by 
HepG2 cells, native ITI is likely to be composed of two heavy 
chains linked to two bikunin chains. 
Each heavy chain may also associate to bikunin to give two- 
chain structures corresponding to HC1/bikunin, HC2/bikunin 
(IaLI) and HC3/bikunin (Pal) complexes, respectively. Since 
the major form (Pal) corresponds to the H3 chain, as opposed 
to its low representation among ITI molecules, the ITI-H3 
molecule could be a form of low stability giving rise to high 
levels of Pal. Indeed, the observed ifferences in the respective 
serum concentrations of ITI family members may result from 
a balance between IT/synthesis and metabolic pathways with 
a low stability of particular components, as demonstrated, for 
instance, with human leukocyte lastase [33]. In this respect, it 
is worth noting that HepG2 cells do not synthesise two-chain 
structures which may only be found after partial digestion of 
the ITI molecule with chondroitinase [32] although it has been 
proposed that interleukin 6 induces in HepG2 cells the synthesis 
of a Pal  form whose composition has not been ascertained [34]. 
The present ITI heavy-chain antisera were shown to be unex- 
pectedly highly specific as further confirmed by the results 
obtained on foetal calf sera (ITI, HC2/bikunin). They allowed 
a better understanding of ITI synthesis and maturation i  cellu- 
lar models [32,35] and moreover permitted a very simple anal- 
ysis of all ITI family members in complex mixtures, thereby 
suggesting alternatives to their structuring. However, the mech- 
anism responsible for the coexistence of ITI and HC/bikunin 
forms in serum, i.e. direct synthesis or transition/degradation, 
has yet to be elucidated. 
Acknowledgements: We thank N. Porchet for secretarial assistance, F. 
Muschio for photographic artwork and J.C. Barr6 for expert reading 
of the manuscript. 
References 
[1] Chen, L., Mao, S.J.T. and Larsen, W.J. (1992) J. Biol. Chem. 267, 
12380 12386. 
[2] Camaioni, A., Hascall, V.C., Yanagishita, M. and Salustri, A. 
(1993) J. Biol. Chem. 268, 20473 20841. 
[3] Chen, L., Mao, S.J.T., McLean, L.R., Powers, R.W. and Larsen, 
W.J. (1994) J. Biol. Chem. 269, 28282 28287. 
[4] Bourguignon, J., Vercaigne, D., Sesbofi6, R., Martin, J.P. and 
Salier, J.R (1983) FEBS Lett. 162, 379-383. 
[5] Bourguignon, J. Diarra-Mehrpour, M., Sesboii6, R., Frain, M., 
Sala-Tr6pat, J.M., Martin, J.P. and Salier, J.E (1985) Biochem. 
Biophys. Res. Commun. 131, 1146 1153. 
[6] Kaumeyer, J.F., Polazzi, J.O. and Kotick, M.R (1986) Nucleic 
Acids Res. 14, 7839 7850. 
[7] Bourguignon, J.  Sesboti6, R., Diarra-Mehrpour, M., Daveau, M. 
and Martin, J.P. (1989) Biochem. J. 261,305 308. 
[8] Odum, L. (1992) Int. J. Biochem. 24, 215-222. 
[9] Diarra-Mehrpour, M., Bourguignon, J., Bost, F., Sesbofi6, R., 
Muschio, F., Sarafan, N. and Martin, J.P. (1992) Biochim. Bio- 
phys. Acta 1132, 114~118. 
[10] Gebhard, W., Schreitmfiller, T., Hochstrasser, K. and Wachter, E. 
(1988) FEBS Lett. 229, 63-67. 
[11] Bourguignon, J. Diarra-Mehrpour, M., Thiberville, L., Bost, F., 
Sesboii6, R. and Martin, J.P. (1993) Eur. J. Biochem. 212, 771- 
776. 
[12] Diarra-Mehrpour, M., Bourguignon, J., Sesboii6, R., Matt6i, 
M.G., Passage, E., Salier, J.R and Martin, J.R (1989) Eur. J. 
Biochem. 179, 147-154. 
[13] Enghild, J.J., Thogersen, I.B., Pizzo, S.V. and Salvesen, G. (1989) 
J. Biol. Chem. 264, 15975 15981. 
[14] Rouet, R, Daveau, M. and Salier, J.R (1992) Biol. Chem. Hoppe 
Seyler 373, 1019-1024. 
[15] Jessen, T.E., Faarvang, K.L. and Ploug, M. (1988) FEBS Lett. 
230, 195-200. 
[16] Enghild, J.J., Salvesen, G., Hefta, S.A., Thogersen, I.B., 
Rutherfurd, S. and Pizzo, S.V. (1991) J. Biol. Chem. 266, 747- 
751. 
[17] Enghild, J.J., Salvesen, G., Thogersen, I.B., Valnickova, Z., Pizzo, 
S.V. and Hefta, S.A. (1993) J. Biol. Chem. 268, 8711-8716. 
[18] Morelle, W., Capon, C., Balduyck, M., Sauti~re, R, Kouach, M., 
Michalski, C., Fournet, B. and Mizon, J. (1994) Eur. J. Biochem. 
221, 881-888. 
[19] Salier, J.R, Sesbo/i6, R., Vercaigne, D., Bourguignon, J. and Mar- 
tin, J.R (1983) Anal. Biochem. 133, 336-343. 
[20] Salier, J.R, Diarra-Mehrpour, M., Sesbofi6, R., Bourguignon, J.
Benarous, R., Ohkubo, I., Kurachi, K. and Martin, J.R (1987) 
Proc. Natl. Acad. Sci. USA 84, 8272-8276. 
[21] Sambrook, J., Fritsch, E.F. and Maniatis, T. (1989) in: Molecular 
Cloning: A Laboratory Manual, pp. 1.82 1.84, Cold Spring Har- 
bor Laboratory Press, Cold Spring Harbor. 
[22] Redinbaugh, M.G. and Campbell, W.H. (1985) Anal. Biochem. 
147, 144-147. 
[23] Malki, N., Balduyck, M., Maes, R, Capon, C., Mizon, C., Han, 
K.K., Tartar, A., Fournet, B. and Mizon, J. (1992) Biol. Chem. 
Hoppe Seyler 373, 1009-1018. 
[24] Laemmli, U.K. (1970) Nature (London) 227, 68~685. 
[25] Bonner, W.M. and Laskey, R.A. (1974) Eur. J. Biochem. 46, 
83 86. 
[26] Salier, J.R, Martin, J.R, Lambin, R, McPhee, H. and Hochstras- 
ser, K. (1980) Anal. Biochem. 109, 273-283. 
[27] Towbin, H., Staehelin, T. and Gordon, J. (1979) Proc. Natl. Acad. 
Sci. USA 76, 43504354. 
[28] Sternberger, L.A., Hardy, Jr., RH., Cuculis, J.J. and Meyer, H.G. 
(1970) J. Histochem. Cytochem. 18, 315 333. 
[29] Castillo, G.M. and Templeton, D.M. (1993) FEBS Lett. 318, 292 
296. 
[30] Sarafan, N., Martin, J.R, Bourguignon, J. Borghi, H., Call6, A., 
Sesboii6, R. and Diarra-Mehrpour, M. (1995) Eur. J. Biochem. 
227, 808 815. 
[31] Wisniewski, H.G., Burgess, W.H., Oppenheim, J.D. and Vilcek, 
J. (1994) Biochemistry 33, 7423 7429. 
[32] H6ron, A., Bourguignon, J. Call6, A., Borghi, H., Sesboii6, R., 
Diarra-Mehrpour, M. and Martin, J.P. (1994) Biochem. J. 302, 
573 580. 
[33] Balduyck, M., Piva, F., Mizon, C., Maes, P., Malki, N., Gressier, 
B., Michalski, C. and Mizon, J. (1993) Biol. Chem. Hoppe Seyler 
374, 895-901. 
[34] Koj, A., Korzus, E., Baumann, H., Nakamura, T. and Travis, J. 
(1993) Biol. Chem. Hoppe Seyler 374, 193 201. 
[35] H~ron, A., Borghi, H., Call6, A., Bourguignon, J., Diarra- 
Mehrpour, M., Martin, J.R and Sesboii6, R. (1995) Cell. Biol. Int. 
19, 593 602. 
